Arrowhead Pharmaceuticals, Inc.

ARWR Healthcare Biotechnology

Arrowhead Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended September 2025) was $829.4 million, up 23,258.2% from fiscal 2024. In the quarter to June 2026, revenue grew 171.0%, EPS fell 7.94%, free cash flow fell 15.4% and total debt rose 259.5%, each against the same quarter a year earlier.

55.90 2.60 −4.44%
Market cap
$8.3B
P/E
0.0×
Fwd P/E
−23.1×
Dividend yield
—
F-score
5/9
Altman Z
2.98
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(64.91%) (46.90%) 65.38% (0.47%)

+8 more TTM periods

Piotroski F-Score
— — 6 —
ROA
(18.32%) (15.67%) 15.45% (0.13%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(18.16%) (15.68%) 16.78% (0.14%)
Average Days of Receivables
4.66 9.20 73.23 3.00
Free Cash Flow per Share
(0.52) (0.36) 2.35 1.17
Free Cash Flow
(75.11) (50.87) 322.01 156.89
Other line items

Show all line items

Columns are period end dates